Hepatitis C

Clinical Trials·Hepatitis C·News·Pharmaceuticals

Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed

Atea Pharmaceuticals shares rose 1.5% to $4.60 Wednesday after reporting Phase 1 data showing its bemnifosbuvir/ruzasvir hepatitis C combo has low risk for drug-drug interactions. The company expects key Phase 3 trial results in mid-2026 and around year-end. Biotech stocks broadly traded higher. Atea’s market cap stood near $364 million.

May 27, 2026

2 ASX Dividend Shares for Reliable Passive Income: Telstra and Woolworths
May 27, 2026, 6:24 PM EDT. Dividend investing requires more than chasing high yields; sustainability matters. Telstra (ASX: TLS) offers a defensive income play with its essential telecommunications services and strong mobile network, despite growth and regulatory risks. Woolworths (ASX: WOW), a supermarket giant, benefits from steady demand for groceries and essentials, backed by scale and trusted brand. Both companies provide franked dividends and resilience through economic cycles, making them reliable choices for investors seeking stable, passive income on the ASX.